Worse Prognosis in Heart Failure Patients with 30-Day Readmission
Ying-Chang Tung, Shing-Hsien Chou, Kuan-Liang Liu, I-Chang Hsieh, Lung-Sheng Wu, Chia-Pin Lin, Ming-Shien Wen, Pao-Hsien Chu, Ying-Chang Tung, Shing-Hsien Chou, Kuan-Liang Liu, I-Chang Hsieh, Lung-Sheng Wu, Chia-Pin Lin, Ming-Shien Wen, Pao-Hsien Chu
Abstract
Background: Heart failure (HF) readmission results in substantial expenditure on HF management. This study aimed to evaluate the readmission rate, outcome, and predictors of HF readmission.
Methods: Patients with reduced left ventricular ejection fraction (LVEF < 40%) who were admitted for acute decompensation of de novo HF were enrolled to analyze readmission rate, mortality and predictors of readmission.
Results: A total of 433 de novo HF patients with LVEF < 40% were enrolled during the period August 2013 to December 2014. The in-hospital and 6-month mortality rates were 3.9% and 15.2%, respectively. In those patients surviving the index HF hospitalization, the 30-day and 6-month readmission rates were 10.9% and 27%, respectively. At the end of the 6-month follow-up, the readmission group had higher mortality than the non-readmission group (27.66% vs. 10.36%; p = 0.001). The survivors of the 30-day readmission had similar mortality rates at 6 months, regardless of the cause of readmission (cardiovascular vs. non-cardiovascular: 25% vs. 30.43%, p = 0.677). Among all the parameters, prescription of beta blockers independently reduced the risk of 30-day readmission (odds ratio 0.15; 95% confidence interval 0.02-0.99; p = 0.049).
Conclusions: Those HF patients who suffered from 30-day readmission had worse prognosis at the 6-month follow-up. Regardless of the readmission causes, the patients surviving the 30-day readmission had similar mortality rates at 6-month follow-up. These results underscored the importance of reducing readmission as a means to improve HF outcome.
Keywords: Heart failure; Prognosis; Readmission.
Figures
Source: PubMed